Publicaciones científicas

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021

07-jun-2022 | Revista: Journal of Translational Medicine

Paolo A Ascierto  1 , Antonio Avallone  2 , Nina Bhardwaj  3 , Carlo Bifulco  4 , Sergio Bracarda  5 , Joshua D Brody  6 , Luigi Buonaguro  7 , Sandra Demaria  8 , Leisha A Emens  9 , Robert L Ferris  10 , Jérôme Galon  11 , Samir N Khleif  12 , Christopher A Klebanoff  13 , Tamara Laskowski  14 , Ignacio Melero  15 , Chrystal M Paulos  16 , Sandro Pignata  17 , Marco Ruella  18 , Inge Marie Svane  19 , Janis M Taube  20 , Bernard A Fox  21 , Patrick Hwu  22 , Igor Puzanov  23


Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches.

These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes.

However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies.The virtual Immunotherapy Bridge (December 1st-2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.

CITA DEL ARTÍCULO  J Transl Med. 2022 Jun 7;20(1):257. doi: 10.1186/s12967-022-03471-y